A Single-arm, Single-center, Prospective Clinical Study of Adebelimab Combined With Chemotherapy for First-line Treatment of Sequential Adebelimab Plus Apatinib Maintenance Therapy in Patients With Extensive-stage Small Cell Lung Cancer A study of adebelimab in combination with chemotherapy in the fi...
patient blood samples, and tissues. We have demonstrated that RK-10 binds to PD-L1 positive tumor cells -breast, retinoblastoma, and lung cancer cell lines using flow cytometry. Flow cytometry using RK-10 was also performed in whole blood spiked with PD-L1 expressing cells, and squamous cell ...
3. Agilent Technologies, Inc. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC 4. S. Gadgeel , et al. 1296O ESMO2017-Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2+L1NSCLC: Results from the randomized OAK study 5. Achim R...
21. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint pd-l1 ihc assay comparison project. J Thorac Oncol. 2017;12(2):208-222. 22. Ye M, Huang D, Zhang Q, et al. Heterogeneous programmed death-liga...
3. Agilent Technologies, Inc. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC 4. S. Gadgeel , et al. 1296O ESMO2017-Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2+L1NSCLC: Results from the randomized OAK study ...
3. Agilent Technologies, Inc. PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC 4. S. Gadgeel , et al. 1296O ESMO2017-Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2+L1NSCLC: Results from the randomized OAK study ...